Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
Habenicht
U F
UF
Research Laboratories of Schering AG, Berlin (West) and Bergkamen, Federal Republic of Germany.
Schröder
H
H
el Etreby
M F
MF
Neumann
F
F
D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017373:Cyproterone Acetate; D005260:Female; D005485:Flutamide / Q000627:therapeutic use; D005966:Glucuronidase / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006168:Guinea Pigs; D007668:Kidney / Q000201:enzymology; D008297:Male; D051379:Mice; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D012733:Sex Differentiation / Q000187:drug effects; D013997:Time Factors
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D005485:Flutamide; D003534:Cyproterone; D005966:Glucuronidase; C030741:lutrelin acetate